Zeke Capital Advisors LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.9% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,172 shares of the biopharmaceutical company’s stock after selling 9,014 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Gilead Sciences were worth $898,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also made changes to their positions in the business. Advisors Preferred LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth $26,000. First Financial Corp IN grew its position in shares of Gilead Sciences by 286.4% during the 3rd quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 401 shares in the last quarter. Legacy Advisors LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth $37,000. Evolution Wealth Advisors LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth $46,000. Finally, Motco grew its position in shares of Gilead Sciences by 213.6% during the 2nd quarter. Motco now owns 690 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 470 shares in the last quarter. 79.67% of the stock is currently owned by institutional investors.
A number of equities analysts have recently issued reports on GILD shares. Morgan Stanley set a $82.00 price target on Gilead Sciences and gave the stock a “hold” rating in a research report on Monday, July 15th. Mizuho set a $81.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, October 15th. BMO Capital Markets set a $82.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $68.00 to $88.00 in a research report on Monday, July 15th. Finally, BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $81.36.
Shares of NASDAQ GILD opened at $64.91 on Monday. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67. The stock has a market capitalization of $82.21 billion, a P/E ratio of 10.55, a price-to-earnings-growth ratio of 2.96 and a beta of 1.10. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $74.80. The business has a fifty day moving average price of $64.33 and a 200 day moving average price of $65.36.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.14. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.54 billion. During the same period last year, the business posted $1.91 earnings per share. The firm’s revenue was down 2.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.69 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.88%. The ex-dividend date of this dividend was Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.